Neutropenia occurring during treatment with vesnarinone (OPC-8212).
Bertolet
B D
BD
Department of Internal Medicine, University of Florida Health Sciences Center, Gainesville.
White
B G
BG
Pepine
C J
CJ
D002311:Cardiomyopathy, Dilated / Q000188:drug therapy; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005060:Europe / Q000453:epidemiology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology / Q000628:therapy; D011719:Pyrazines; D011804:Quinolines / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D014481:United States / Q000453:epidemiology
D002316:Cardiotonic Agents; D011719:Pyrazines; D011804:Quinolines; D016179:Granulocyte Colony-Stimulating Factor; C041667:vesnarinone